Always discuss potential side effects with your healthcare provider
In contrast, the STEP-1 trial with semaglutide 2.4 mg (Wegovy) showed an average weight loss of about 15% over 68 weeks
it might look mostly right, but it won't open the lock anymore
Inform your doctor or pharmacist of any questions or concerns you may have about the medication
For routine concerns, schedule an appointment if gastrointestinal side effects persist beyond the first month of treatment or significantly impact your quality of life
According to Diabetes Daily, a recent survey by Thrivable, a diabetes market research firm, demonstrated that people with type 1 diabetes who use GLP-1 drugs are far more likely to think positively about the future of diabetes treatment: 41.2 percent of GLP-1 users reported feeling optimistic, compared with a mere 5.6 percent of nonusers